Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP)

MMWR Recomm Rep. 1991 Jan 11;40(RR-1):1-7.


These recommendations include information on use of two vaccines recently licensed for use with infants: Haemophilus b Conjugate Vaccine (Diphtheria CRM197 Protein Conjugate) (HbOC), manufactured by Praxis Biologics, Inc., and Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PRP-OMP), manufactured by Merck Sharp and Dohme, newly licensed for use with infants. This statement also updates recommendations for use of these and other Haemophilus b conjugate vaccines with older children and adults.

Publication types

  • Guideline

MeSH terms

  • Adult
  • Bacterial Outer Membrane Proteins* / administration & dosage
  • Bacterial Outer Membrane Proteins* / adverse effects
  • Bacterial Proteins* / administration & dosage
  • Bacterial Proteins* / adverse effects
  • Bacterial Vaccines* / administration & dosage
  • Bacterial Vaccines* / adverse effects
  • Child, Preschool
  • Diphtheria Toxoid / administration & dosage
  • Drug Administration Schedule
  • Haemophilus Infections / prevention & control*
  • Haemophilus Vaccines*
  • Haemophilus influenzae / immunology*
  • Humans
  • Infant
  • Polysaccharides, Bacterial* / administration & dosage
  • Polysaccharides, Bacterial* / adverse effects
  • Vaccination / standards


  • Bacterial Outer Membrane Proteins
  • Bacterial Proteins
  • Bacterial Vaccines
  • Diphtheria Toxoid
  • Haemophilus Vaccines
  • Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate
  • Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine
  • Polysaccharides, Bacterial
  • HibTITER protein, Haemophilus influenzae